temozolomide has been researched along with Adrenal Cancer in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "We determined neuroblastoma cell viability after treatment with cabozantinib alone and in combination with 13-cis-retinoic acid, topotecan, and temozolomide using MTT assays." | 7.81 | Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. ( Scorsone, K; Woodfield, SE; Zage, PE; Zhang, L, 2015) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 7.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "We report on the efficacy and safety of short-term administration of temozolomide, an inhibitor of nucleoside incorporation, in a 60-year-old woman with widespread hepatic metastases from a malignant paraganglioma." | 7.75 | Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. ( Bravo, EL; Gill, I; Kalmadi, SR, 2009) |
| "Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs." | 5.48 | Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. ( Bertorelle, R; Ferrara, AM; Iacobone, M; Lombardi, G; Meringolo, D; Nardin, M; Opocher, G; Pambuku, A; Schiavi, F; Zagonel, V; Zovato, S, 2018) |
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| " Targeting dopamine and somatostatin receptors on corticotroph adenomas with cabergoline or pasireotide, or both, controls cortisol production in up to 40% of patients." | 5.01 | Advances in the medical treatment of Cushing's syndrome. ( Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R, 2019) |
| "The therapeutic options for metastatic pheochromocytomas/paragangliomas (mPPGLs) include chemotherapy with cyclophosphamide/vincristine/dacarbazine (CVD), temozolomide monotherapy, radionuclide therapies, and tyrosine kinase inhibitors such as sunitinib." | 4.31 | Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study. ( Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bornstein, SR; Dischinger, U; Fischer, A; Fliedner, SMJ; Grossman, AB; Hantel, C; Kloos, S; Kroiss, M; Maurer, J; Mohr, H; Nölting, S; Pacak, K; Pamporaki, C; Pellegata, NS; Reincke, M; Remde, H; Reul, A; Robledo, M; Timmers, HJLM; Wang, K, 2023) |
| "We determined neuroblastoma cell viability after treatment with cabozantinib alone and in combination with 13-cis-retinoic acid, topotecan, and temozolomide using MTT assays." | 3.81 | Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. ( Scorsone, K; Woodfield, SE; Zage, PE; Zhang, L, 2015) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 3.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| " We investigated the effect of LB1, a small molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A), on its ability to inhibit a low growth fraction and highly drug-resistant solid neuroendocrine tumor, such as metastatic pheochromocytoma (PHEO)." | 3.77 | Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. ( Bernardo, M; Chiang, J; Lonser, R; Lu, J; Martiniova, L; Pacak, K; Zhuang, Z, 2011) |
| "We report on the efficacy and safety of short-term administration of temozolomide, an inhibitor of nucleoside incorporation, in a 60-year-old woman with widespread hepatic metastases from a malignant paraganglioma." | 3.75 | Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. ( Bravo, EL; Gill, I; Kalmadi, SR, 2009) |
| "Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs." | 1.48 | Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. ( Bertorelle, R; Ferrara, AM; Iacobone, M; Lombardi, G; Meringolo, D; Nardin, M; Opocher, G; Pambuku, A; Schiavi, F; Zagonel, V; Zovato, S, 2018) |
| "The presence of subcutaneous metastases raised the suspicion for metastatic melanoma; however, pathological confirmation remained the ultimate tool to reach the final diagnosis." | 1.39 | Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. ( Ejaz, S; Habra, MA; Henderson, SA; Shawa, H, 2013) |
| "Temozolomide was studied using a continuous exposure at final concentrations from 0." | 1.30 | Activity of temozolomide against human tumor colony-forming units. ( Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Perez, K | 1 |
| Jacene, H | 1 |
| Hornick, JL | 1 |
| Ma, C | 1 |
| Vaz, N | 1 |
| Brais, LK | 1 |
| Alexander, H | 1 |
| Baddoo, W | 1 |
| Astone, K | 1 |
| Esplin, ED | 1 |
| Garcia, J | 1 |
| Halperin, DM | 1 |
| Kulke, MH | 2 |
| Chan, JA | 1 |
| Wang, K | 2 |
| Crona, J | 1 |
| Beuschlein, F | 2 |
| Grossman, AB | 2 |
| Pacak, K | 3 |
| Nölting, S | 2 |
| Urquhart, C | 3 |
| Fleming, B | 3 |
| Harper, I | 3 |
| Aloj, L | 3 |
| Armstrong, R | 3 |
| Hook, L | 3 |
| Long, AM | 3 |
| Jackson, C | 3 |
| Gallagher, FA | 3 |
| McLean, MA | 3 |
| Tarpey, P | 3 |
| Kosmoliaptsis, V | 3 |
| Nicholson, J | 3 |
| Hendriks, AEJ | 3 |
| Casey, RT | 3 |
| Fischer, A | 1 |
| Kloos, S | 1 |
| Remde, H | 1 |
| Dischinger, U | 1 |
| Pamporaki, C | 1 |
| Timmers, HJLM | 1 |
| Robledo, M | 1 |
| Fliedner, SMJ | 1 |
| Maurer, J | 1 |
| Reul, A | 1 |
| Bechmann, N | 1 |
| Hantel, C | 1 |
| Mohr, H | 1 |
| Pellegata, NS | 1 |
| Bornstein, SR | 1 |
| Kroiss, M | 1 |
| Auernhammer, CJ | 1 |
| Reincke, M | 1 |
| Ferrara, AM | 1 |
| Lombardi, G | 1 |
| Pambuku, A | 1 |
| Meringolo, D | 1 |
| Bertorelle, R | 1 |
| Nardin, M | 1 |
| Schiavi, F | 1 |
| Iacobone, M | 1 |
| Opocher, G | 1 |
| Zagonel, V | 1 |
| Zovato, S | 1 |
| Feelders, RA | 1 |
| Newell-Price, J | 1 |
| Pivonello, R | 1 |
| Nieman, LK | 1 |
| Hofland, LJ | 1 |
| Lacroix, A | 1 |
| Ejaz, S | 1 |
| Shawa, H | 1 |
| Henderson, SA | 1 |
| Habra, MA | 1 |
| Hadoux, J | 1 |
| Favier, J | 1 |
| Scoazec, JY | 1 |
| Leboulleux, S | 1 |
| Al Ghuzlan, A | 1 |
| Caramella, C | 1 |
| Déandreis, D | 1 |
| Borget, I | 1 |
| Loriot, C | 1 |
| Chougnet, C | 1 |
| Letouzé, E | 1 |
| Young, J | 1 |
| Amar, L | 1 |
| Bertherat, J | 1 |
| Libé, R | 1 |
| Dumont, F | 1 |
| Deschamps, F | 1 |
| Schlumberger, M | 1 |
| Gimenez-Roqueplo, AP | 1 |
| Baudin, E | 1 |
| Zhang, L | 1 |
| Scorsone, K | 1 |
| Woodfield, SE | 1 |
| Zage, PE | 1 |
| Bravo, EL | 1 |
| Kalmadi, SR | 1 |
| Gill, I | 1 |
| Martiniova, L | 1 |
| Lu, J | 1 |
| Chiang, J | 1 |
| Bernardo, M | 1 |
| Lonser, R | 1 |
| Zhuang, Z | 1 |
| Kanold, J | 1 |
| Paillard, C | 1 |
| Tchirkov, A | 1 |
| Lang, P | 1 |
| Kelly, A | 1 |
| Halle, P | 1 |
| Isfan, F | 1 |
| Merlin, E | 1 |
| Marabelle, A | 1 |
| Rochette, E | 1 |
| Deméocq, F | 1 |
| Stuart, K | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Clark, JW | 1 |
| Muzikansky, A | 1 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
| Raymond, E | 1 |
| Izbicka, E | 1 |
| Soda, H | 1 |
| Gerson, SL | 1 |
| Dugan, M | 1 |
| Von Hoff, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism[NCT05255900] | 20 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for temozolomide and Adrenal Cancer
| Article | Year |
|---|---|
Targeted Therapies in Pheochromocytoma and Paraganglioma.
Topics: Adrenal Gland Neoplasms; Humans; Paraganglioma; Pheochromocytoma; Randomized Controlled Trials as To | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
Advances in the medical treatment of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodi | 2019 |
1 trial available for temozolomide and Adrenal Cancer
| Article | Year |
|---|---|
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
10 other studies available for temozolomide and Adrenal Cancer
| Article | Year |
|---|---|
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Humans; Mutation; Paraganglioma; Pheochromocytoma; Retrospective Studies; S | 2022 |
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Topics: Adrenal Gland Neoplasms; Brain Neoplasms; Cardiovascular Diseases; Cohort Studies; Humans; Iodine Ra | 2023 |
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Leucine Zipper Tr | 2018 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2014 |
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Anilides; Animals; Antineoplastic Combined Chemothera | 2015 |
Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Middle Aged | 2009 |
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2011 |
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Neoplasms | 2012 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 1997 |